Sequentially, revenue from operations grew by 2.9 per cent, whereas profit after tax (PAT) fell by 4.5 per cent ...

Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.

The drug offered more relief than a placebo in clinical trials, though it does not appear more effective than other pain ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...